HomeCompareVRPX vs VYM

VRPX vs VYM: Dividend Comparison 2026

VRPX yields 500000.00% · VYM yields 2.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VRPX wins by $4.663521010693878e+33M in total portfolio value
10 years
VRPX
VRPX
● Live price
500000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.663521010693878e+33M
Annual income
$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00
Full VRPX calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.41%
Share price
$145.48
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$278.55
Full VYM calculator →

Portfolio growth — VRPX vs VYM

📍 VRPX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVRPXVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VRPX + VYM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VRPX pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VRPX
Annual income on $10K today (after 15% tax)
$42,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr
VYM
Annual income on $10K today (after 15% tax)
$205.23/yr
After 10yr DRIP, annual income (after tax)
$236.77/yr
At 15% tax rate, VRPX beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VRPX + VYM for your $10,000?

VRPX: 50%VYM: 50%
100% VYM50/50100% VRPX
Portfolio after 10yr
$2.331760505346939e+33M
Annual income
$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.96%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VRPX buys
0
VYM buys
1
PoliticianChamberTickerTypeAmountDate
Carol Devine Miller🏢 House$VYM▲ Buy$15,001 - $50,0002022-11-02
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVRPXVYM
Forward yield500000.00%2.41%
Annual dividend / share$2.00$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.663521010693878e+33M$27.8K
Annual income after 10y$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$278.55
Total dividends collected$4.6634009849658873e+33M$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: VRPX vs VYM ($10,000, DRIP)

YearVRPX PortfolioVRPX Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$50,010,700$50,000,000.00$11,151$241.44+$50.00MVRPX
2$233,748,371,262$233,694,859,813.08$12,413$246.79+$233748.36MVRPX
3$1,021,074,511,412,696$1,020,824,400,655,446.10$13,794$251.79+$1021074511.40MVRPX
4$4,168,597,328,794,951,700$4,167,504,779,067,739,000.00$15,306$256.47+$4168597328794.94MVRPX
5$15,905,475,114,600,665,000,000$15,901,014,715,458,854,000,000.00$16,960$260.84+$15905475114600664.00MVRPX
6$56,718,938,532,531,060,000,000,000$56,701,919,674,158,435,000,000,000.00$18,768$264.92+$56718938532531060736.00MVRPX
7$189,031,807,435,623,860,000,000,000,000$188,971,118,171,394,040,000,000,000,000.00$20,745$268.71+$1.8903180743562385e+23MVRPX
8$588,799,810,476,518,260,000,000,000,000,000$588,597,546,442,562,100,000,000,000,000,000.00$22,905$272.24+$5.8879981047651824e+26MVRPX
9$1,714,064,268,114,722,600,000,000,000,000,000,000$1,713,434,252,317,512,700,000,000,000,000,000,000.00$25,265$275.51+$1.7140642681147225e+30MVRPX
10$4,663,521,010,693,878,300,000,000,000,000,000,000,000$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$27,842$278.55+$4.663521010693878e+33MVRPX

VRPX vs VYM: Complete Analysis 2026

VRPXStock

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Full VRPX Calculator →

VYMETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this VRPX vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VRPX vs SCHDVRPX vs JEPIVRPX vs OVRPX vs KOVRPX vs MAINVRPX vs VIGVRPX vs DGROVRPX vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.